Variables Affecting Reconstitution Time of Dry Powder for Injection - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Variables Affecting Reconstitution Time of Dry Powder for Injection
The authors describe the factors affecting reconstitution time of dry powder for injection and classifies them as intrinsic and extrinsic parameters.


Pharmaceutical Technology


17. A.K. Bansal, "Product Development Issues of Powders for Injection," Pharm. Technol. 26 (3), 122–132 (2002).

18. A. Kristl et al., "Polymorphism and Pseudopolymorphism: Influencing the Dissolution Properties of the Guanine Derivative Acyclovir," Int. J. Pharm. 139 (1–2), 231–235 (1996).

19. M. Borrnstein and S.M. Carone, "Method for Preparing Sterile Essentially Amorphous Cephazolin for Reconstitution for Parenteral Administration," US Patent 4002748 (1977).

20. A. Saleki-Gerhardt et al., "Assessment of Disorder in Crystalline Solids," Int. J. Pharm. 101 (3), 237–247 (1994).

21. S.J. Bai et al., "Quantification of Glycine Crystallinity by Near- Infrared (NIR) Spectroscopy," J. Pharm. Sci. 93 (10), 2439–2447 (2004).

22. P. Niemela et al., "Quantitative Analysis of Amorphous Content of Lactose Using CCD-Raman Spectroscopy," J. Pharm. Biomed. Anal. 37 (5), 907–911 (2005).

23. R. Lefort et al., "Solid State NMR and DSC Methods for Quantifying the Amorphous Content in Solid Dosage Forms: an Application to Ball-Milling of Trehalose," Int. J. Pharm. 280 (1–2), 209–219 (2004).

24. L. Mackin et al., "Quantification of Low Levels (<10%) of Amorphous Content in Micronised Active Batches Using Dynamic Vapor Sorption and Isothermal Microcalorimetry," Int. J. Pharm. 231 (2), 227–236 (2002).

25. T. Sebhatu et al., "Assessment of the Degree of Disorder in Crystalline Solids by Isothermal Microcalorimetry," Int. J. Pharm. 104 (2), 135–144 (1994).

26. D. Giron et al., "Quantitation of Amorphicity by Microcalorimetry," J. Therm. Anal. Calorim. 48 (3), 465–472 (1997).

27. J. Han et al., "Applications of Pressure Differential Scanning Calorimetry in the Study of Pharmaceutical Hydrates. II. Ampicillin Trihydrate," Int. J. Pharm. 170 (1), 63–72 (1998).

28. S. Guinot and F. Leveiller, "The Use of MTDSC to Assess the Amorphous Phase Content of a Micronised Drug Substance," Int. J. Pharm. 192 (1), 63–75 (1999).

29. E. Katainen et al., "Evaluation of the Amorphous Content of Lactose by Solution Calorimetry and Raman Spectroscopy," Talanta 68 (1), 1–5 (2005).

30. V.P. Lehto et al., "The Comparison of Seven Different Methods to Quantify the Amorphous Content of Spray-Dried Lactose," Powder Technol. 167 (2), 85–93 (2006).

31. B. Freudig et al., "Dispersion of Powders in Liquids in a Stirred Vessel," Chem. Eng. Process. 38 (4–6), 525–532 (1999).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here